Microbicides Development Programme
The Microbicides Development Programme (MDP) is a not-for-profit, African-European partnership, which was established to develop vaginal microbicides to reduce the risk of HIV infection in women. MDP was launched in 2000 and conducts clinical trials to test the safety and effectiveness of potential microbicides. It also carries out research in basic science, models the potential impact of microbicides and explores factors surrounding their acceptability.
Studies
Latest News
20 July 2010 - MDP partners congratulate CAPRISA trial team
The MDP partners congratulate the trial team and study participants on successfully completing the CAPRISA 004 trial of the 1% tenofovir microbicide gel, and are delighted to see proof for the concept of microbicides.
During the course of the programme, seven feasibility studies have been completed in 5 sub-Saharan countries, with each study run by an African academic partner.
The MDP 301 phase III trial is the culmination of several years of collaborative work in the field of HIV prevention. Over 20,000 women have been screened for these studies, and 9,404 were enrolled in MDP 301. MDP identified and referred over 5,000 women who needed access to anti-retroviral therapy for HIV, thus helping clinics meet targets set by their national governments for roll-out of treatment. MDP has continued to assess potential microbicides in the laboratory, taken a second microbicide candidate from bench to clinic, conducted a clinical distribution study, and developed epidemiological and economic models to determine potential microbicide impact on the HIV epidemic.
